Teclistamab
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: BCMAxCD3, JNJ-64007957, teclistamab-cqyv, tecvayli
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Teclistamab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2022. DrugCentral lists 2 molecular targets, including TNFRSF17 and CD3E|CD3G|CD3D. Recorded indications include Relapsed or refractory multiple myeloma.
- Molecular targets: TNFRSF17 and CD3E|CD3G|CD3D (2 listed in DrugCentral).
- Indications: Relapsed or refractory multiple myeloma.
- ATC code: L01FX24 (Other monoclonal antibodies and antibody drug conjugates).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Relapsed or refractory multiple myeloma
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Tumor necrosis factor receptor superfamily member 17 | TNFRSF17 | other | Kd 9.74 |
| T-cell surface glycoprotein CD3 | CD3E|CD3G|CD3D | other | Kd 7.55 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-10-25 | FDA | — | JANSSEN BIOTECH | Yes |
| 2022-08-23 | EMA | — | JANSSEN-CILAG INTERNATIONAL N.V. |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FX24 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label
- FDA label
- HCSC label
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Cytokine release syndrome | 3088.9 |
| Immune effector cell-associated neurotoxicity syndrome | 1395.4 |
| COVID-19 | 229.4 |
| Hypogammaglobulinaemia | 221.9 |
| Infection | 163.2 |
| IVth nerve paralysis | 152.9 |
| IgA nephropathy | 139.8 |
| Neutropenia | 138.7 |
| Neurotoxicity | 95.9 |
| Progressive multifocal leukoencephalopathy | 92.4 |
| COVID-19 pneumonia | 89.7 |
| Pneumonia | 89.7 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 2119595-80-9 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Teclistamab used for?
DrugCentral lists the following indications for Teclistamab: Relapsed or refractory multiple myeloma.
How does Teclistamab work?
Its molecular targets in DrugCentral include TNFRSF17 and CD3E|CD3G|CD3D.
When was Teclistamab first approved?
Teclistamab was first approved by the EMA in 2022.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5706 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4594505 — compound record and bioactivity
- DrugBank DB16655 — drug record
- FDA UNII 54534MX6Z9 — substance identity
- DailyMed: FDA labels for Teclistamab — current prescribing information (label search)
- UniProt Q02223 (TNFRSF17) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.